81 related articles for article (PubMed ID: 16515579)
1. Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period.
Jaaback KS; Ludeman L; Clayton NL; Hirschowitz L
Int J Gynecol Cancer; 2006; 16 Suppl 1():123-8. PubMed ID: 16515579
[TBL] [Abstract][Full Text] [Related]
2. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study.
Barda G; Menczer J; Chetrit A; Lubin F; Beck D; Piura B; Glezerman M; Modan B; Sadetzki S;
Am J Obstet Gynecol; 2004 Apr; 190(4):1039-45. PubMed ID: 15118638
[TBL] [Abstract][Full Text] [Related]
3. Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology--a prospective comparative study.
Schnack TH; Sørensen RD; Nedergaard L; Høgdall C
Gynecol Oncol; 2014 Nov; 135(2):278-84. PubMed ID: 25168689
[TBL] [Abstract][Full Text] [Related]
4. Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data.
Barclay M; Gildea C; Poole J; Hirschowitz L; Menon U; Nordin A
Int J Gynecol Cancer; 2016 Jan; 26(1):56-65. PubMed ID: 26509852
[TBL] [Abstract][Full Text] [Related]
5. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Rosendahl M; Høgdall CK; Mosgaard BJ
Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
[TBL] [Abstract][Full Text] [Related]
6. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic spread among women with primary peritoneal carcinoma.
Eltabbakh GH; Mount SL
J Surg Oncol; 2002 Nov; 81(3):126-31. PubMed ID: 12407724
[TBL] [Abstract][Full Text] [Related]
8. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
[TBL] [Abstract][Full Text] [Related]
9. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma.
Ben-Baruch G; Sivan E; Moran O; Rizel S; Menczer J; Seidman DS
Gynecol Oncol; 1996 Mar; 60(3):393-6. PubMed ID: 8774644
[TBL] [Abstract][Full Text] [Related]
10. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan.
Chao KC; Chen YJ; Juang CM; Lau HY; Wen KC; Sung PL; Fang FY; Twu NF; Yen MS
Taiwan J Obstet Gynecol; 2013 Mar; 52(1):81-4. PubMed ID: 23548224
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
12. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
13. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
[TBL] [Abstract][Full Text] [Related]
14. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
15. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
16. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
17. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
18. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
19. Presence of a sarcomatous component outside the ovary is an adverse prognostic factor for primary ovarian malignant mixed mesodermal/mullerian tumors: a clinicopathologic study of 47 cases.
Kunkel J; Peng Y; Tao Y; Krigman H; Cao D
Am J Surg Pathol; 2012 Jun; 36(6):831-7. PubMed ID: 22588065
[TBL] [Abstract][Full Text] [Related]
20. Malignant mixed müllerian tumor of primary mesenteric origin.
Mikami M; Kuwabara Y; Tanaka K; Komiyama S; Ishikawa M; Hirose T
Int J Gynecol Cancer; 2005; 15(6):1249-53. PubMed ID: 16343225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
